Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, a consumer health company focused on brands such as Advil, Centrum, and Sensodyne, covers the month of April 2026. The report, dated April 27, 2026, details transactions in the company's own shares under a share buyback programme announced on March 12, 2026.
Key Financial Metrics and Share Transactions
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on share repurchase activity:
- Total Shares Purchased: 8,444,107 ordinary shares for cancellation.
- Transaction Period: April 20, 2026, to April 24, 2026.
- Price Range: Shares were purchased at prices ranging from a low of 342.70 pence to a high of 357.10 pence per share.
- Post-Transaction Capital: Registered share capital stands at 8,902,639,582 ordinary shares, with 12,281,053 held as treasury shares.
- Voting Rights: The number of ordinary shares with voting rights is 8,890,358,529.
Material Changes
The primary material change reported is the reduction of outstanding shares through the buyback programme. The filing does not disclose changes in operational performance, financial position, or market conditions compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It serves strictly as a regulatory disclosure of share transactions in compliance with the Market Abuse Regulation (EU) No 596/2014 as applied in the UK.
Investor Verification Checklist
- Verify the total cost of the buyback by multiplying the volume-weighted average prices by the share volumes for each trading day.
- Confirm the updated number of voting shares (8,890,358,529) for compliance with FCA Disclosure Guidance and Transparency Rules.
- Review the full breakdown of individual trades available via the provided London Stock Exchange link for granular execution details.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or quarterly earnings release for revenue and profit metrics.